INDOCO
Small CapIndoco Remedies Limited
Pharma
Indoco Remedies Limited operates in Hospitals / Diagnostics, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
One read, four checks
75+ is strong, 60-74 is usable, 45-59 is mixed, and below 45 needs caution. These are research lenses, not buy/sell instructions.
Weak fundamentals, management trust needs verification, price trend argues for patience, and recent execution is weak.
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
low confidence · 0/0 claims checked
Timing lens: price trend and sector relative strength.
Rolling lens: recent quarterly delivery, not the latest single-result score.
Quarter ended 31 Mar 2026
Good · 55/100Rev +22% YoY · margin expansion · +7% QoQ
| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹476 Cr | +22.1% | +7.0% |
| EBITDA | ₹50 Cr | +5100.0% | +56.3% |
| Operating margin | 10.0% | +1000 bps | +300 bps |
| PAT | ₹-24 Cr | NDF | NDF |
| PAT margin | -5.0% | +547 bps | +148 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Issuer presentation review pending
Indoco Remedies Limited operates in Hospitals / Diagnostics, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 31 Mar 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trend score and candlestick chart
44NeutralSMA20 -3.2% / mo
Technical chart
INDOCOdaily · 1Y-23.5%Technical trend read
Bearish setupTrend is weak — long-term trend unclear. RSI 48.
- SMA20 falling (~3.8% over last month) — short-term momentum negative.
- RSI(14) at 48 — sideways, no extreme reading.
- MACD below signal, histogram expanding negatively — bearish momentum building.
- 24% off 52W high · 27% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Valuation, score drivers, trust methodology, financials, and peers
Use these sections after reviewing the decision summary, latest result, thesis, management accountability, and technical timing above.
Fundamental score breakdown
OVERVALUEDWhy this score?
Top U-Score contributors and drags from the latest stored fundamentals.
Positive drivers
- FCF yield is supportive at 4.9%.
- Cash flow contributes 7/10 to the score.
- Balance sheet contributes 5/15 to the score.
Main drags
- Quality is weaker at 0/20; verify the latest quarterly trend.
- Growth is weaker at 4/25; verify the latest quarterly trend.
- Valuation is weaker at 7/30; verify the latest quarterly trend.
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Score history
12 stored score snapshots. Latest stored move: +0 points.
Factor attribution
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Weak Trust: Claim history is still being built. It ranks around the 13th percentile of the scored universe and 8th percentile within Pharma. Main check: results consistency is weak at 27/100.
Mixed Trust Lite: Promoter holding is 58.9%. Key concern: 5 recent quarters had PAT decline worse than 25% YoY.
Management or financial behaviour needs caution. Demand stronger valuation compensation.
overall median 67 · Pharma: 8th pctile, median 70 · Small: 15th pctile, median 65
0 documents indexed, but claim history is not strong enough yet.
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Weak Trust · low confidenceRead Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Trust positives
- ▸Promoter holding is 58.9%.
- ▸Promoter pledge is zero.
- ▸FCF yield is positive at 4.8%.
- ▸7 years of positive FCF.
Trust risks
- ▸5 recent quarters had PAT decline worse than 25% YoY.
- ▸Debt/equity is 1.16.
- ▸Interest coverage is 1.2x.
- ▸ROCE is low at 0.9%.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Intrinsic value
Fundamentals
Valuation
- P/E
- —
- P/B
- 1.96
- EV/EBITDA
- 10.94
- Market Cap
- 1842.00Cr
Profitability
- ROE
- -9.42%
- ROCE
- 0.93%
- ROA
- -3.82%
- Dividend Y
- 0.10%
Growth (CAGR)
- Revenue 5Y
- 8.00%
- EPS 5Y
- -14.00%
- Revenue 3Y
- 3.00%
- EPS 3Y
- -15.00%
Balance Sheet
- Debt/Equity
- 1.16
- Interest Coverage
- 1.16×
- Altman Z
- 2.19
- Book Value
- 102.00
Cash Flow
- FCF Yield
- 4.89%
- FCF Positive Y
- 7/5
- OCF
- 192.00 Cr
- EPS TTM
- -10.31
Shareholding
- Promoter Hold
- 58.86%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 20%
Financial History
Updated 9/6/2026
Revenue
₹ CrNet Profit
₹ CrReturn on Equity
%Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.